Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis

Clinical and Applied Immunology Reviews

Volumn 4, Issue 4, 2004, Pages 239-262

  Vossenaar, Erik R ^a   van Venrooij, Walther J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti CCP antibodies; Citrullinated proteins; Rheumatoid arthritis; Serological marker diagnosis

Indexed keywords

AUTOANTIGEN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPATHOGENESIS; JOINT DESTRUCTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SEROLOGY; SYMPTOMATOLOGY;

EID: 1842567307     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cair.2003.11.001     Document Type: Review

References (168)

1. Gabriel S.E. The epidemiology of rheumatoid arthritis Rheum Dis Clin North Am 27 2001 269-281
2. Silman A.J. Pearson J.E. Epidemiology and genetics of rheumatoid arthritis Arthritis Res 4 Suppl 3 2002 S265-S272
3. Kvien T.K. Epidemiology of disability in rheumatoid arthritis Rheumatology (Oxford) 41 2002 121-123
4. Turesson C. Jacobsson L. Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality Rheumatology (Oxford) 38 1999 668-674
5. Turesson C. O'Fallon W.M. Crowson C.S. Gabriel S.E. Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis J Rheumatol 29 2002 62-67
6. Smolen J.S. Steiner G. Therapeutic strategies for rheumatoid arthritis Nat Rev Drug Discov 2 2003 473-488
7. Bukhari M.A. Wiles N.J. Lunt M. Harrison B.J. Scott D.G. Symmons D.P. et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study Arthritis Rheum 48 2003 46-53
8. Landewe R.B. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing Arthritis Rheum 48 2003 1-5
9. Lard L.R. Visser H. Speyer I. vander Horst-Bruinsma I.E. Zwinderman A.H. Breedveld F.C. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies Am J Med 111 2001 446-451
10. Arnett F.C. Edworthy S.M. Bloch D.A. McShane D.J. Fries J.F. Cooper N.S. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 1988 315-324
11. Kaarela K. Kauppi M.J. Lehtinen K.E. The value of the ACR 1987 criteria in very early rheumatoid arthritis Scand J Rheumatol 24 1995 279-281
12. Saraux A. Berthelot J.M. Chales G. Le Henaff C. Thorel J.B. Hoang S. et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later Arthritis Rheum 44 2001 2485-2491
13. van Venrooij W.J. Hazes J.M. Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis Neth J Med 60 2002 383-388
14. Kirwan J.R. Quilty B. Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment? Clin Exp Rheumatol 15 Suppl 17 1997 S15-S25
15. Mageed R.A. The RF antigen. In: van Venrooij W.J. Maini R.N. (Eds.), Manual of biological markers of disease 1996 1-27 Kluwer Academic Publishers Dordrecht, The Netherlands
16. Lisse J.R. Does rheumatoid factor always mean arthritis? Postgrad Med 94 1993 133-134 139
17. Palosuo T. Tilvis R. Strandberg T. Aho K. Filaggrin related antibodies among the aged Ann Rheum Dis 62 2003 261-263
18. van Boekel M.A. Vossenaar E.R. van den Hoogen F.H. van Venrooij W.J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value Arthritis Res 4 2002 87-93
19. Hassfeld W. Steiner G. Hartmuth K. Kolarz G. Scherak O. Graninger W. et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis Arthritis Rheum 32 1989 1515-1520
20. Steiner G. Hartmuth K. Skriner K. Maurer F.I. Sinski A. Thalmann E. et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex J Clin Invest 90 1992 1061-1066
21. Steiner G. Skriner K. Hassfeld W. Smolen J.S. Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins-a link between RA, SLE and MCTD Mol Biol Rep 23 1996 167-171
22. Mimori T. Suganuma K. Tanami Y. Nojima T. Matsumura M. Fujii T. et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases Proc Natl Acad Sci USA 92 1995 7267-7271
23. Menard H.A. El-Amine M. The calpain-calpastatin system in rheumatoid arthritis Immunol Today 17 1996 545-547
24. Mulder A.H. Horst G. van-Leeuwen M.A. Limburg P.C. Kallenberg C.G. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations Arthritis Rheum 36 1993 1054-1060
25. Schnabel A. Hauschild S. Gross W.L. Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases Int Arch Allergy Immunol 109 1996 201-206
26. Tan E.M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine Adv Immunol 33 1982 167-240
27. Warlow R.S. Antibodies to extractable nuclear antigens (ENA) in rheumatoid arthritis assayed by ELISA. A clinicopathological correlation Scand J Rheumatol 15 1986 185-192
28. Ronnelid J. Lysholm J. Engstrom L.A. Klareskog L. Heyman B. Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response Arthritis Rheum 37 1994 1023-1029
29. Boissier M.C. Chiocchia G. Texier B. Fournier C. Pattern of humoral reactivity to type II collagen in rheumatoid arthritis Clin Exp Immunol 78 1989 177-183
30. D'Mello F. Howard C.R. An improved selection procedure for the screening of phage display peptide libraries J Immunol Methods 247 2001 191-203
31. Atta M.S. Lim K.L. Ala'deen D.A. Powell R.J. Todd I. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus Ann Rheum Dis 54 1995 117-124
32. Schaller M. Burton D.R. Ditzel H.J. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease Nat Immunol 2 2001 746-753
33. Matsumoto I. Lee D.M. Goldbach-Mansky R. Sumida T. Hitchon C.A. Schur P.H. et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders Arthritis Rheum 48 2003 944-954
34. Bläss S. Specker C. Lakomek H.J. Schneider E.M. Schwochau M. Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies Ann Rheum Dis 54 1995 355-360
35. Bläss S. Union A. Raymackers J. Schumann F. Ungethum U. Muller-Steinbach S. et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis Arthritis Rheum 44 2001 761-771
36. Bläss S. Meier C. Vohr H.W. Schwochau M. Specker C. Burmester G.R. The p68 autoantigen characteristic of rheumatoid arthritis is reactive with carbohydrate epitope specific autoantibodies Ann Rheum Dis 57 1998 220-225
37. Bläss S. Haferkamp C. Specker C. Schwochau M. Schneider M. Schneider E.M. Rheumatoid arthritis: autoreactive T cells recognising a novel 68k autoantigen Ann Rheum Dis 56 1997 317-322
38. Bodman-Smith M.D. Corrigall V.M. Kemeny D.M. Panayi G.S. BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals Rheumatology (Oxford) 42 2003 637-644
39. Corrigall V.M. Bodman-Smith M.D. Fife M.S. Canas B. Myers L.K. Wooley P. et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis J Immunol 166 2001 1492-1498
40. Despres N. Boire G. Lopez L.F. Menard H.A. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis J Rheumatol 21 1994 1027-1033
41. Hayem G. Chazerain P. Combe B. Elias A. Haim T. Nicaise P. et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis J Rheumatol 26 1999 7-13
42. Hueber W. Hassfeld W. Smolen J.S. Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis Rheumatology (Oxford) 38 1999 155-159
43. Xu S. Tang F. Shi L. Gan X. Shi Y. Cheng L. et al. Anti-Sa antibody in Chinese rheumatoid arthritis Chin Med J (Engl) 111 1998 204-207
44. Menard H.A. Lapointe E. Rochdi M.D. Zhou Z.J. Insights into rheumatoid arthritis derived from the Sa immune system Arthritis Res 2 2000 429-432
45. Escalona M. Lopez-Longo F.J. Gonzalez C.M. Monteagudo I. Rodriguez-Mahou M. Grau R. et al. Anti-Sa sera from patients with rheumatoid arthritis contain at least 2 different subpopulations of anti-Sa antibodies J Rheumatol 29 2002 2053-2060
46. Asaga H. Yamada M. Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages Biochem Biophys Res Commun 243 1998 641-646
47. Vossenaar E.R. Radstake T.R. van der Heijden A. Van Mansum W.A.M. Dieteren C. de Rooij D.J. et al. Expression and activity of citrullinating PAD enzymes in monocytes and macrophages Ann Rheum Dis 2003 In press
48. Nienhuis R.L.F. Mandema E.A. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor Ann Rheum Dis 23 1964 302-305
49. Hoet R.M. van Venrooij W.J. The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen J. Kalden J.R. Maini R.N. (Eds.), Rheumatoid arthritis 1992 299-318 Springer-Verlag Berlin
50. Smit J.W. Sondag-Tschroots I.R. Aaij C. Feltkamp T.E. Feltkamp-Vroom T.M. The antiperinuclear factor:: II. A light microscopical and immunofluorescence study on the antigenic substrate Ann Rheum Dis 39 1980 381-386
51. Hoet R.M. Boerbooms A.M. Arends M. Ruiter D.J. van Venrooij W.J. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin Ann Rheum Dis 50 1991 611-618
52. Young B.J. Mallya R.K. Leslie R.D. Clark C.J. Hamblin T.J. Anti-keratin antibodies in rheumatoid arthritis BMJ 2 1979 97-99
53. Quismorio F.P.Jr. Kaufman R.L. Beardmore T. Mongan E.S. Reactivity of serum antibodies to the keratin layer of rat esophagus in patients with rheumatoid arthritis Arthritis Rheum 26 1983 494-499
54. Simon M. Girbal E. Sebbag M. Gomes-Daudrix V. Vincent C. Salama G. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis J Clin Invest 92 1993 1387-1393
55. Sebbag M. Simon M. Vincent C. Masson B.C. Girbal E. Durieux J.J. et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies J Clin Invest 95 1995 2672-2679
56. Gan S.Q. McBride O.W. Idler W.W. Markova N. Steinert P.M. Organization, structure, and polymorphisms of the human profilaggrin gene Biochemistry 29 1991 9432-9440
57. Pearton D.J. Dale B.A. Presland R.B. Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution J Invest Dermatol 119 2002 661-669
58. Resing K.A. al-Alawi N. Blomquist C. Fleckman P. Dale B.A. Independent regulation of two cytoplasmic processing stages of the intermediate filament-associated protein filaggrin and role of Ca(2+) in the second stage J Biol Chem 268 1993 25139-25145
59. Mack J.W. Steven A.C. Steinert P.M. The mechanism of interaction of filaggrin with intermediate filaments. The ionic zipper hypothesis J Mol Biol 232 1993 50-66
60. Manabe M. Sanchez M. Sun T.T. Dale B.A. Interaction of filaggrin with keratin filaments during advanced stages of normal human epidermal differentiation and in ichthyosis vulgaris Differentiation 48 1991 43-50
61. Simon M. Vincent C. Haftek M. Girbal E. Sebbag M. Gomes-Daudrix V. et al. The rheumatoid arthritis-associated autoantibodies to filaggrin label the fibrous matrix of the cornified cells but not the profilaggrin-containing keratohyalin granules in human epidermis Clin Exp Immunol 100 1995 90-98
62. Hoet R.M. Voorsmit R.A. van Venrooij W.J. The perinuclear factor, a rheumatoid arthritis-specific autoantigen, is not present in keratohyalin granules of cultured buccal mucosa cells Clin Exp Immunol 84 1991 59-65
63. Schellekens G.A. de Jong B.A. van den Hoogen F.H. van de Putte L.B. van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies J Clin Invest 101 1998 273-281
64. Vossenaar E.R. Zendman A.J.W. van Venrooij W.J. Pruijn G. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease Bioessays 25 2003 1106-1118
65. Girbal N.E. Durieux J.J. Arnaud M. Dalbon P. Sebbag M. Vincent C. et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues J Immunol 162 1999 585-594
66. Masson-Bessière C. Sebbag M. Durieux J.J. Nogueira L. Vincent C. Girbal-Neuhauser E. et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum Clin Exp Immunol 119 2000 544-552
67. Smeets T.J. Vossenaar E.R. Kraan M.C. Van Mansum W.A.M. Raats J.M. van Venrooij W.J. et al. Expression of citrulline-containing antigens in RA synovium Arthritis Res 3 2002 P4 [Abstr.]
68. Reparon-Schuijt C.C. van Esch W.J. van Kooten C. Schellekens G.A. de Jong B.A. van Venrooij W.J. et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis Arthritis Rheum 44 2001 41-47
69. Ishida-Yamamoto A. Hashimoto Y. Manabe M. O'Guin W.M. Dale B.A. Iizuka H. Distinctive expression of filaggrin and trichohyalin during various pathways of epithelial differentiation Br J Dermatol 137 1997 9-16
70. Tarcsa E. Marekov L.N. Mei G. Melino G. Lee S.C. Steinert P.M. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin J Biol Chem 271 1996 30709-30716
71. Vincent C. Simon M. Sebbag M. Girbal N.E. Durieux J.J. Cantagrel A. et al. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis J Rheumatol 25 1998 838-846
72. Palosuo T. Lukka M. Alenius H. Kalkkinen N. Aho K. Kurki P. et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay Int Arch Allergy Immunol 115 1998 294-302
73. Slack S.L. Mannik M. Dale B.A. Diagnostic value of antibodies to filaggrin in rheumatoid arthritis J Rheumatol 25 1998 847-851
74. Nogueira L. Sebbag M. Vincent C. Arnaud M. Fournie B. Cantagrel A. et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis Ann Rheum Dis 60 2001 882-887
75. Vincent C. Nogueira L. Sebbag M. Chapuy-Regaud S. Arnaud M. Letourneur O. et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis Arthritis Rheum 46 2002 2051-2058
76. Schellekens G.A. Visser H. de Jong B.A. van den Hoogen F.H. Hazes J.M. Breedveld F.C. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide Arthritis Rheum 43 2000 155-163
77. Hiemstra H.S. Benckhuijsen W.E. Amons R. Rapp W. Drijfhout J.W. A new hybrid resin for stepwise screening of peptide libraries combined with single bead Edman sequencing J Pept Sci 4 1998 282-288
78. de Koster H.S. Amons R. Benckhuijsen W.E. Feijlbrief M. Schellekens G.A. Drijfhout J.W. The use of dedicated peptide libraries permits the discovery of high affinity binding peptides J Immunol Methods 187 1995 179-188
79. van Boekel M.A. de Jong B.A. Drijfhout J.W. de Koning P.E. van Delft J. van Venrooij W.J. Selection of diagnostic marker peptides for autoimmune diseases using synthetic peptide libraries. In: Conrad K. Humbel R.L. Muerer M. Shoenfeld Y. Tan E.M. (Eds.), Autoantigens and autoantibodies: diagnostic tools and clues to understanding autoimmunity. Report on the 5th Dresden symposium on autoantibodies 2000 140-145 Pabst Science Publishers Lengerich
80. Bizzaro N. Mazzanti G. Tonutti E. Villalta D. Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis Clin Chem 47 2001 1089-1093
81. Bas S. Perneger T.V. Seitz M. Tiercy J.M. Roux-Lombard P. Guerne P.A. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors Rheumatology (Oxford) 41 2002 809-814
82. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies Am Clin Lab 21 2002 34-36
83. Pinheiro G.C. Scheinberg M.A. Aparecida D.S. Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis Ann Intern Med 139 2003 234-235
84. Lee D.M. Schur P.H. Clinical utility of the anti-CCP assay in patients with rheumatic diseases Ann Rheum Dis 62 2003 870-874
85. van Rossum M. van Soesbergen R. de Kort S. ten Cate R. Zwinderman A.H. de Jong B. et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis J Rheumatol 30 2003 825-828
86. Avcin T. Cimaz R. Falcini F. Zulian F. Martini G. Simonini G. et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis Ann Rheum Dis 61 2002 608-611
87. Prahalad S. Glass D.N. Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis? Arthritis Res 4 suppl 3 2003 303-310
88. Isenberg D.A. Horsfall A.C. Systemic lupus erythematosus in adults. In: Madisson P.J. Isenberg D.A. Woo P. Glass D.N. (Eds.), Oxford textbook of rheumatology 1998 1145-1180 Oxford University Press Oxford
89. Mediwake R. Isenberg D.A. Schellekens G.A. van Venrooij W.J. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis Ann Rheum Dis 60 2001 67-68
90. Olivieri I. Palazzi C. Padula A. Hepatitis C virus and arthritis Rheum Dis Clin North Am 29 2003 111-122
91. Zuckerman E. Yeshurun D. Rosner I. Management of hepatitis C virus-related arthritis BioDrugs 15 2001 573-584
92. Leone N. Pellicano R. Ariata M. Maiocco I. Modena V. Marietti G. et al. Mixed cryoglobulinaemia and chronic hepatitis C virus infection: the rheumatic manifestations J Med Virol 66 2002 200-203
93. Newkirk M.M. Rheumatoid factors: what do they tell us? J Rheumatol 29 2002 2034-2040
94. Wener M.H. Hutchinson K. Morishima C. Gretch D.R. Antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia Arthritis Rheum 2004 in press
95. Salvador G. Gomez A. Vinas O. Ercilla G. Canete J.D. Munoz-Gomez J. et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) 42 2003 972-975
96. Nielen M.M.J. Van Schaardenburg D. Reesink H.W.R. van de Stadt R.J. van der Horst-Bruinsma I. de Koning M.H.M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum 2003 In press
97. Rantapää-Dahlqvist S. de-Jong B.A. Berglin E. Hallmans G. Wadell G. Stenlund H. et al. Antibodies against citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 48 2003 2741-2749
98. Jansen A.L. van der Horst-Bruinsma I. Van Schaardenburg D. Van De Stadt R. De Koning M. Dijkmans B.A. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis J Rheumatol 29 2002 2074-2076
99. van Gaalen F.A. Linn-Rasker S.P. van Venrooij W.J. de Jong B.A. Breedveld F.C. Verweij C.L. et al. In undifferentiated arthritis, autoantibodies to cyclic citrullinated peptides (CCP) predict progression to rheumatoid arthritis: a prospective cohort study Arthritis Rheum 2003 In press
100. Munoz F.S. Alvarez D.R. Gonzalez T.J. Balsa A. Richi P. Fontan G. et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis J Rheumatol 26 1999 2572-2577
101. Bas S. Perneger T.V. Mikhnevitch E. Seitz M. Tiercy J.M. Roux-Lombard P. et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis Rheumatology (Oxford) 39 2000 1082-1088
102. Paimela L. Gripenberg M. Kurki P. Leirisalo R.M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis Ann Rheum Dis 51 1992 743-746
103. Paimela L. Palosuo T. Aho K. Lukka M. Kurki P. Leirisalo-Repo M. et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis Ann Rheum Dis 60 2001 32-35
104. Forslin K. Vincent C. Serre G. Svensson B. Antifilaggrin antibodies in early rheumatoid arthritis may predict radiological progression Scand J Rheumatol 30 1902 221-224
105. van Jaarsveld C.H. ter Borg E.J. Jacobs J.W. Schellekens G.A. Gmelig-Meyling F.H. van Booma-Frankfort C. et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis Clin Exp Rheumatol 17 1999 689-697
106. Kroot E.J. de Jong B.A. van Leeuwen M.A. Swinkels H. van den Hoogen F.H. van't Hof M. et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum 43 2000 1831-1835
107. Visser H. Le Cessie S. Vos K. Breedveld F.C. Hazes J.M. How to diagnose rheumatoid arthritis early? A prediction model for persistent (erosive) arthritis Arthritis Rheum 46 2002 357-365
108. Vencovsky J. Machacek S. Sedova L. Kafkova J. Gatterova J. Pesakova V. et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis Ann Rheum Dis 62 2003 427-430
109. Meyer O. Labarre C. Dougados M. Goupille P. Cantagrel A. Dubois A. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage Ann Rheum Dis 62 2003 120-126
110. van der Heijde D.M. van Riel P.L. van Leeuwen M.A. 't Hof M.A. van Rijswijk M.H. van de Putte L.B. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients Br J Rheumatol 31 1992 519-525
111. Jansen L.M. Van Schaardenburg D. van der Horst-Bruinsma I. Van De Stadt R. De Koning M. Dijkmans B.A. The predictive value of anti-cyclic citrullinated Peptide antibodies in early arthritis J Rheumatol 30 2003 1691-1695
112. Maddali S, Manetti R, Melchiorre D, Turchini S, Boccaccini P, Vanni L, Maggi E. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis. Department of Internal Medicine, University of Florence, Florence, Italy; submitted for publication.
113. Rus'd A.A. Ikejiri Y. Ono H. Yonekawa T. Shiraiwa M. Kawada A. et al. Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse Eur J Biochem 259 1999 660-669
114. Rogers G. Winter B. McLaughlan C. Powell B. Nesci A. Hair follicle peptidylarginine deiminase Exp Dermatol 8 1992 362-363
115. Kanno T. Kawada A. Yamanouchi J. Yosida-Noro C. Yoshiki A. Shiraiwa M. et al. Human peptidylarginine deiminase type III: molecular cloning and nucleotide sequence of the cDNA, properties of the recombinant enzyme, and immunohistochemical localization in human skin J Invest Dermatol 115 2000 813-823
116. Guerrin M. Ishigami A. Mechin M.C. Nachat R. Valmary S. Sebbag M. et al. cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I Biochem J 370 2003 167-174
117. Watanabe K. Akiyama K. Hikichi K. Ohtsuka R. Okuyama A. Senshu T. Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues Biochim Biophys Acta 966 1988 375-383
118. Nagata S. Senshu T. Peptidylarginine deiminase in rat and mouse hemopoietic cells Experientia 46 1990 72-74
119. Ishigami A. Ohsawa T. Asaga H. Akiyama K. Kuramoto M. Maruyama N. Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin Arch Biochem Biophys 407 2002 25
120. Nakashima K. Hagiwara T. Ishigami A. Nagata S. Asaga H. Kuramoto M. et al. Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha, 25-dihydroxyvitamin D(3) J Biol Chem 274 1999 27786-27792
121. Asaga H. Nakashima K. Senshu T. Ishigami A. Yamada M. Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils J Leukoc Biol 70 2001 46-51
122. Nakashima K. Hagiwara T. Yamada M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes J Biol Chem 277 2002 49562-49568
123. Wright P.W. Bolling L.C. Calvert M.E. Sarmento O.F. Berkeley E.V. Shea M.C. et al. ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets Dev Biol 256 2003 74-89
124. Suzuki A. Yamada R. Chang X. Tokuhiro S. Sawada T. Suzuki M. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis Nat Genet 34 2003 395-402
125. Masson-Bessière C. Sebbag M. Girbal-Neuhauser E. Nogueira L. Vincent C. Senshu T. et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin J Immunol 166 2001 4177-4184
126. Serre G. Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease Joint Bone Spine 68 2001 103-105
127. McCarthy D.J. Cheung H.S. Origin and significance of rice bodies in synovial fluid [letter] Lancet 2 1982 715-716
128. Weinberg J.B. Pippen A.M. Greenberg C.S. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis Arthritis Rheum 34 1991 996-1005
129. Feldmann M. Brennan F.M. Maini R.N. Rheumatoid arthritis Cell 85 1996 307-310
130. Takahara H. Okamoto-H Sugawara K. Calcium-dependent properties of peptidylarginine deiminase from rabbit skeletal muscle Agric Biol Chem 50 1986 2899-2904
131. Schwab B.L. Guerini D. Didszun C. Bano D. Ferrando-May E. Fava E. et al. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis Cell Death Differ 9 2002 818-831
132. Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 9 2002 561-573
133. Mizoguchi M. Manabe M. Kawamura Y. Kondo Y. Ishidoh K. Kominami E. et al. Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro J Histochem Cytochem 46 1998 1303-1309
134. Hagiwara T. Nakashima K. Hirano H. Senshu T. Yamada M. Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes Biochem Biophys Res Commun 290 2002 979-983
135. Pettit A.R. Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol Cell Biol 77 1999 420-427
136. Cutolo M. Sulli A. Barone A. Seriolo B. Accardo S. Macrophages, synovial tissue and rheumatoid arthritis Clin Exp Rheumatol 11 1993 331-339
137. Rodenburg R.J. Ganga A. van Lent P.L. van de Putte L.B. van Venrooij W.J. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis Arthritis Rheum 43 2000 1941-1950
138. Morgan D.W. Marschall L.A. In vivo models of inflammation 1999 Birkhauser Verlag Basel, Switserland
139. Vossenaar E.R. Nijenhuis S. van Helsen M.M. van der Heijden A. Senshu T. van den Berg W.B. et al. Citrullination of Synovial Proteins in Murine Models of Rheumatoid Arthritis Arthritis Rheum 48 2003 2489-2500
140. Chapuy-Ragaud S. Nogueira L. Clavel C. Sebbag M. Vincent C. Serre G. Subclass distribution of IgG autoantibodies to deiminated fibrinogen in rheumatoid arthritis Arthritis Res 5 2003 S2 [Abstr.]
141. Meulenbroek A.J. Zeijlemaker W.P. Human IgG subclasses: useful diagnostic markers for immunocompetence 2000 CLB Amsterdam, The Netherlands
142. Hill J.A. Southwood S. Sette A. Jevnikar A.M. Bell D.A. Cairns E. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule J Immunol 171 2003 538-541
143. Goldbach-Mansky R. Lee J. McCoy A. Hoxworth J. Yarboro C. Smolen J.S. et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset Arthritis Res 2 2000 236-243
144. Berglin E. Padyukov L. Hallmans G. van Venrooij W.J. Klareskog L. Rantapää-Dahlquist S. Presence of the shared epitope genes increase the predictive value of antibodies against cyclic citrullinated peptide (CCP) for rheumatoid arthritis. Dept of public health and clinical medicine, University hospital, Umeå, Sweden: Arthritis Rheum 48 9 Suppl 2003 S678
145. Utz P.J. Gensler T.J. Anderson P. Death, autoantigen modifications, and tolerance Arthritis Res 2 2000 101-114
146. Casciola-Rosen L. Andrade F. Ulanet D. Wong W.B. Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity J Exp Med 190 1999 815-826
147. Utz P.J. Hottelet M. Schur P.H. Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus J Exp Med 185 1997 843-854
148. Zampieri S. Degen W. Ghirardello A. Doria A. van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus Ann Rheum Dis 60 2001 72-76
149. Piacentini M. Colizzi V. Tissue transglutaminase: apoptosis versus autoimmunity Immunol Today 20 1999 130-134
150. Rodenburg R.J. Raats J.M. Pruijn G.J. van Venrooij W.J. Cell death: a trigger of autoimmunity? Bioessays 22 2000 627-636
151. Matzinger P. The danger model: a renewed sense of self Science 296 2002 301-305
152. Goronzy J.J. Weyand C.M. B cells as a therapeutic target in autoimmune disease Arthritis Res 5 2003 131-135
153. Dorner T. Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets Curr Opin Rheumatol 15 2003 246-252
154. Silverman G.J. Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy Arthritis Rheum 48 2003 1484-1492
155. Cambridge G. Leandro M.J. Edwards J.C. Ehrenstein M.R. Salden M. Bodman-Smith M. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis Arthritis Rheum 48 2003 2146-2154
156. Maini R.N. Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis Ann Rev Med 51 2000 207-229
157. Alessandri C, Bombardieri M, Del Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF[alpha] therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. "La Sapienza", Roma, Italy: Ann Rheum Dis 2004; in press.
158. Lard L.R. van Gaalen F.A. Schonkeren J.J.M. Pieterman E.J. Stoeken G. Vos K. et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis Arthritis Rheum 47 2003 1841-1848
159. Lalani I. Bhol K. Ahmed A.R. Interleukin-10: biology, role in inflammation and autoimmunity Ann Allergy Asthma Immunol 79 1997 469-484
160. Mocellin S. Panelli M.C. Wang E. Nagorsen D. Marincola F.M. The dual role of IL-10 Trends Immunol 24 2003 36-43
161. Rousset F. Garcia E. Defrance T. Peronne C. Vezzio N. Hsu D.H. et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes Proc Natl Acad Sci USA 89 1992 1890-1893
162. Senecal J.L. Rothfield N.F. Oliver J.M. Immunoglobulin M autoantibody to vimentin intermediate filaments J Clin Invest 69 1982 716-721
163. Brown C. Pedersen J. Underwood J.R. Gust I. Toh B.H. Autoantibodies to intermediate filaments in acute viral hepatitis A, B and non-A, non-B are directed against vimentin J Clin Lab Immunol 19 1986 1-4
164. Yang Y. Fujita J. Bandoh S. Ohtsuki Y. Yamadori I. Yoshinouchi T. et al. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia Clin Exp Immunol 128 2002 169-174
165. Yasuda M. Nobunaga M. Antibodies to cytoskeletal systems in normal human serum Fukuoka Igaku Zasshi 81 1990 323-330
166. Robinson W.H. DiGennaro C. Hueber W. Haab B.B. Kamachi M. Dean E.J. et al. Autoantigen microarrays for multiplex characterization of autoantibody responses Nat Med 8 2002 295-301
167. Hueber W. Utz P.J. Steinman L. Robinson W.H. Autoantibody profiling for the study and treatment of autoimmune disease Arthritis Res 4 2002 290-295
168. Robinson W.H. Steinman L. Utz P.J. Proteomics technologies for the study of autoimmune disease Arthritis Rheum 46 2002 885-893